Competing interests
Johnson & Johnson, Bayer, Iovance, 4D Pharma, HTG, RCC, Kidney Cancer, Cancer
EMD, ONCOLOGY, EVENTS, KIDNEY CANCER, RCC, CANCER
J.A.K. reports honoraria for scientific advisory board memberships/consulting for Merck, Pfizer, Johnson and Johnson; stock ownership in MedTek, ROMTech; research funding to institution from Mirati, Roche/Genentech, Merck, Elypta. P.M. reports honoraria for scientific advisory boards membership for Mirati Therapeutics, Bristol-Myers Squibb, and Exelixis; consulting fees from Axiom Healthcare; non-branded educational programmes supported by Exelixis and Pfizer; leadership or fiduciary roles as a Medical Steering Committee Member for the Kidney Cancer Association and a Kidney Cancer Scientific Advisory Board Member for KCCure; and research funding from Takeda, Bristol-Myers Squibb, Mirati Therapeutics, and Gateway for Cancer Research. C.L.H. reports consulting fees from Nanobiotix, stock options for scientific advisory board membership from Briacell, research funding to institution from Iovance, Dragonfly, Sanofi, Avenge and Mirati, honoraria from SITC and SWOG. S.F.M. reports consulting relationships with Merck and Johnson & Johnson; and clinical trial support for QED. M.T.C. reports consulting/advisory relationships with ApricityHealth, AstraZeneca, AXDev, EMD Serono, Exelixis, Seagen, and Pfizer; research funding from ApricityHealth, AstraZeneca, Aveo, EMD Serono, Exelixis, Janssen, and Pfizer; honoraria from AstraZeneca, AXDev, BMS, DAVA, EMD Serono, Exelixis, Merck, Roche, Pfizer, Seagen, and SITC; has received support for attending meetings and/or travel from the Kidney Cancer Association; and holds a leadership or fiduciary role as part of the Kidney Cancer Association Steering Committee. A.J.Z. reports consulting/advisory relationships with Amedco, AstraZeneca, Bayer, Biocept, CancerNet, LLC., Incyte, and Pfizer; research funding from Infinity Pharma and Pfizer; and honoraria from Amedco, AstraZeneca, CancerNet, LLC., Janssen-Cilag, McKesson Specialty Health, and Pfizer. A.Y.S. reports research funding from Bristol-Myers Squibb, Eisai, and EMD Serono; and receipt of equipment, materials, drugs, medical writing, gifts or other services from Bristol-Myers Squibb, Eisai, EMD Sereona, and 4D Pharma. I.I.W. reports grants/contracts to their institution from Genentech, HTG Molecular, Merck, Bristol-Myers Squibb, Medimmune, Adaptive, Adaptimmune Therapeutics, EMD Sereno, Pfizer, Takeda, Amgen, Karus, Johnson & Johnson, Bayer, Iovance, 4D Pharma, Novartis, and Akoya; consulting fees from Roche, Bayer, Bristol-Myers Squibb, AstraZeneca, Pfizer, HTG Molecular, Merch, GlaxoSmithKline, GuardantHealth, Novartis, Flame, Sanofi, Janssen, Daiichi Sankyo, Oncocyte, Amgen, and MSD; and payment/honoraria from Medscape, Roche, Pfizer, AstraZeneca, Platform Health, and Merck. D.D. reports honoraria from Chrysalis Biomedical Advisors. E.M., E.R.P., L.M.S.S., C.L.-F., M.L., A.A. have no relevant conflicts to disclose. M.H., C.D.C., P.O., X.Y., and H.D.-T. are employees and stockholders of Mirati Therapeutics, Inc. N.M.T. reports grants/contracts from Bristol-Myers Squibb, Nektar Therapeutics, Calithera Bioscience, Arrowhead Pharmaceuticals, Eisai, and Novartis; and consulting fees from Oncorena; honoraria for advisory meetings, presentations, and educational events from Bristol-Myers Squibb, Nektar Therapeutics, Exelixis, Eisai, Eli Lilly, Oncorena, Calithera, Surface Oncology, Novartis, Ipsen, and Merck Sharp & Dohme; participation on a data safety monitoring board or advisory board as a member of the US RCC Advisory Board Committee for Merck; and is a stockholder of Amgen, Arcturus Therapeutics, Arcus Biosciences, Bellus Health, BioCryst, Corvus Pharmaceuticals, First Trust Amex Biotech, Johnson & Johnson, Merck, Nuvation Bio, Revolution Medicines, Spdr S&P Pharmaceuticals, Surface Oncology, Vanguard Healthcare Solutions, and Xencor.